Raffles Medical Group's stock is soaring 3.26% in intraday trading on Tuesday, following a positive research report from RHB Research. The healthcare provider's shares have gained traction after analyst Shekhar Jaiswal upgraded the stock to "buy" from "neutral" and raised the target price to S$1.08 from S$0.95.
The upgrade comes as RHB Research identifies Raffles Medical as a likely defensive option in the current volatile market environment. Jaiswal notes that the company's healthcare business has normalized, with patient load returning to pre-pandemic levels. Moreover, the analyst expects the hospital business to see higher revenue as its China-based hospitals, previously affected by pandemic restrictions, begin to scale up operations.
Investors appear to be responding positively to the improved outlook and the defensive nature of Raffles Medical's earnings amid macroeconomic uncertainties. The stock's strong performance today reflects growing confidence in the company's ability to navigate the current market conditions and potentially outperform in the healthcare sector.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。